Immunovant, Inc. (NASDAQ:IMVT - Get Free Report) CFO Eva Renee Barnett sold 4,105 shares of the company's stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $24.10, for a total transaction of $98,930.50. Following the completion of the transaction, the chief financial officer now owns 327,064 shares in the company, valued at approximately $7,882,242.40. This represents a 1.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Eva Renee Barnett also recently made the following trade(s):
- On Wednesday, November 20th, Eva Renee Barnett sold 4,174 shares of Immunovant stock. The stock was sold at an average price of $25.45, for a total transaction of $106,228.30.
- On Wednesday, November 20th, Eva Renee Barnett sold 4,174 shares of Immunovant stock. The stock was sold at an average price of $25.45, for a total transaction of $106,228.30.
- On Wednesday, October 16th, Eva Renee Barnett sold 3,271 shares of Immunovant stock. The stock was sold at an average price of $28.79, for a total transaction of $94,172.09.
Immunovant Stock Down 0.6 %
Immunovant stock traded down $0.15 during mid-day trading on Friday, reaching $23.48. The company had a trading volume of 832,137 shares, compared to its average volume of 685,890. Immunovant, Inc. has a 52 week low of $23.08 and a 52 week high of $43.92. The company has a 50 day moving average of $27.07 and a 200-day moving average of $28.58. The firm has a market cap of $3.45 billion, a price-to-earnings ratio of -10.58 and a beta of 0.66.
Immunovant (NASDAQ:IMVT - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.59) by ($0.15). During the same quarter in the previous year, the company earned ($0.45) EPS. On average, analysts predict that Immunovant, Inc. will post -2.73 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several research analysts have recently commented on the stock. Raymond James restated an "outperform" rating and set a $36.00 price target on shares of Immunovant in a research note on Thursday, October 10th. Oppenheimer increased their price target on shares of Immunovant from $47.00 to $53.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 9th. Wolfe Research downgraded shares of Immunovant from an "outperform" rating to a "peer perform" rating in a report on Friday, January 3rd. Wells Fargo & Company decreased their price objective on shares of Immunovant from $47.00 to $45.00 and set an "overweight" rating for the company in a report on Thursday, December 19th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $51.00 price objective on shares of Immunovant in a report on Friday, November 8th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Immunovant presently has an average rating of "Moderate Buy" and an average price target of $47.22.
Read Our Latest Stock Analysis on Immunovant
Institutional Trading of Immunovant
Several large investors have recently added to or reduced their stakes in the company. KBC Group NV increased its position in Immunovant by 46.2% in the 3rd quarter. KBC Group NV now owns 1,936 shares of the company's stock valued at $55,000 after acquiring an additional 612 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Immunovant by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,294 shares of the company's stock valued at $148,000 after acquiring an additional 934 shares in the last quarter. Assetmark Inc. increased its position in Immunovant by 73.8% in the 3rd quarter. Assetmark Inc. now owns 2,891 shares of the company's stock valued at $82,000 after acquiring an additional 1,228 shares in the last quarter. Tyro Capital Management LLC increased its position in Immunovant by 0.6% in the 3rd quarter. Tyro Capital Management LLC now owns 252,149 shares of the company's stock valued at $7,189,000 after acquiring an additional 1,529 shares in the last quarter. Finally, Quest Partners LLC increased its position in Immunovant by 216.7% in the 2nd quarter. Quest Partners LLC now owns 2,610 shares of the company's stock valued at $69,000 after acquiring an additional 1,786 shares in the last quarter. 47.08% of the stock is owned by institutional investors.
Immunovant Company Profile
(
Get Free Report)
Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.
See Also
Before you consider Immunovant, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunovant wasn't on the list.
While Immunovant currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
